Bioventus (BVS) financial statements
Bioventus reported revenue of $568M in fiscal 2025, up 8.9% a year over 6 years.
Net income was $23M and the operating margin 9.5%, against 9.2% in 2019.
Free cash flow was $72M.
The diluted share count rose 52% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Bioventus's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $340M | $321M | $431M | $512M | $512M | $573M | $568M |
| Cost of revenue | $91M | $88M | $128M | $181M | $184M | $185M | $180M |
| Gross profit | $249M | $234M | $303M | $331M | $328M | $388M | $388M |
| Research and development | $11M | $11M | $19M | $24M | $13M | $14M | $12M |
| Selling, general and admin | $198M | $193M | $254M | $332M | $304M | $344M | $314M |
| Operating income | $31M | $21M | $12M | -$167M | -$82M | -$15M | $54M |
| Pre-tax income | $10M | $16M | $9M | -$189M | -$121M | -$52M | $26M |
| Income tax | $2M | $1M | -$2M | -$44M | $85,000 | -$5M | -$2M |
| Net income | $7M | $16M | $19M | -$159M | -$156M | -$36M | $23M |
| EPS (diluted) | — | — | -$0.15 | -$2.59 | -$2.49 | -$0.56 | $0.33 |
| Diluted shares | — | — | 45M | 61M | 63M | 65M | 69M |
| Gross margin | 73.3% | 72.7% | 70.3% | 64.6% | 64.1% | 67.7% | 68.3% |
| Operating margin | 9.2% | 6.6% | 2.8% | -32.7% | -16.0% | -2.7% | 9.5% |
| Net margin | 2.0% | 5.1% | 4.5% | -31.0% | -30.5% | -6.3% | 4.0% |
Balance sheet
Fiscal years, from Bioventus's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $65M | $87M | $44M | $30M | $37M | $42M | $51M |
| Receivables | — | $88M | $125M | $136M | $123M | $127M | $128M |
| Inventory | — | $29M | $62M | $85M | $91M | $92M | $82M |
| Total current assets | — | $212M | $263M | $273M | $268M | $276M | $273M |
| Property, plant and equipment | — | $7M | $23M | $27M | $37M | $27M | $22M |
| Goodwill | — | $50M | $148M | $7M | $7M | $7M | $7M |
| Total assets | — | $494M | $1.2B | $1.4B | $811M | $728M | $684M |
| Total current liabilities | — | $123M | $181M | $304M | $175M | $210M | $160M |
| Long-term debt | — | $173M | $340M | $385M | $367M | $308M | $279M |
| Total liabilities | — | $350M | $618M | $960M | $590M | $542M | $455M |
| Shareholders' equity | — | — | $459M | $325M | $174M | $148M | $184M |
| Net debt | -$65M | $102M | $314M | $388M | $358M | $294M | $243M |
Cash flow
Fiscal years, from Bioventus's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $41M | $72M | $23M | -$14M | $15M | $39M | $75M |
| Capital spending | $2M | $17M | $14M | $1M | $7M | $1M | $3M |
| Free cash flow | $38M | $55M | $9M | -$15M | $8M | $38M | $72M |
| Stock-based compensation | $0 | $0 | $20M | $18M | $3M | $13M | $13M |
| Free cash flow margin | 11.3% | 17.2% | 2.2% | -2.9% | 1.6% | 6.6% | 12.7% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BVS.
Open BVS in InvestinglyQuestions
What was Bioventus's revenue in 2025?
$568M in fiscal 2025, from its 10-K filing.
How much free cash flow does Bioventus generate?
$72M in fiscal 2025 (operating cash flow minus capital spending).
From Bioventus's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.